Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human and Viral microRNA Expression in Acute and Chronic HIV Infections.
Lazzari E, Rozera G, Gagliardini R, Esvan R, Mondi A, Mazzotta V, Camici M, Girardi E, Antinori A, Maggi F, Abbate I. Lazzari E, et al. Among authors: mazzotta v. Viruses. 2024 Mar 23;16(4):496. doi: 10.3390/v16040496. Viruses. 2024. PMID: 38675839 Free PMC article.
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
Vergori A, Cozzi-Lepri A, Tavelli A, Mazzotta V, Azzini AM, Gagliardini R, Mastrorosa I, Latini A, Pellicanò G, Taramasso L, Ceccherini-Silberstein F, Giannella M, Tacconelli E, Marchetti G, Monforte AD, Antinori A; Vax ICONA ORCHESTRA Study group. Vergori A, et al. Among authors: mazzotta v. Int J Infect Dis. 2024 Apr 19;144:107065. doi: 10.1016/j.ijid.2024.107065. Online ahead of print. Int J Infect Dis. 2024. PMID: 38643867 Free article.
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
Matusali G, Vergori A, Cimini E, Mariotti D, Mazzotta V, Lepri AC, Colavita F, Gagliardini R, Notari S, Meschi S, Fusto M, Tartaglia E, Girardi E, Maggi F, Antinori A; HIV‐VAC Study Group. Matusali G, et al. Among authors: mazzotta v. J Med Virol. 2024 Apr;96(4):e29598. doi: 10.1002/jmv.29598. J Med Virol. 2024. PMID: 38624044
Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era.
Vergori A, Cozzi Lepri A, Chiuchiarelli M, Mazzotta V, Metafuni E, Matusali G, Siciliano V, Paulicelli J, Alma E, Siniscalchi A, Sica S, Abruzzese E, Fantoni M, Antinori A, Cingolani A. Vergori A, et al. Among authors: mazzotta v. Int J Infect Dis. 2024 Apr 12;144:107042. doi: 10.1016/j.ijid.2024.107042. Online ahead of print. Int J Infect Dis. 2024. PMID: 38614231 Free article.
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
79 results